DIVIS LABORATORIES
Back to Balance Sheet
|
DIVIS LABORATORIES Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹1,215 Cr | ₹500 Cr | ₹611 Cr | ₹557 Cr | ₹437 Cr |
What is the latest Total Non-Current Liabilities ratio of DIVIS LABORATORIES ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2026 | ₹1,215 Cr |
| Mar2025 | ₹500 Cr |
| Mar2024 | ₹611 Cr |
| Mar2023 | ₹557 Cr |
| Mar2022 | ₹437 Cr |
How is Total Non-Current Liabilities of DIVIS LABORATORIES Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹1,215 Cr | 143.00 | |
| Mar2025 | ₹500 Cr | -18.17 | |
| Mar2024 | ₹611 Cr | 9.69 | |
| Mar2023 | ₹557 Cr | 27.60 | |
| Mar2022 | ₹437 Cr | - | |
Compare Total Non-Current Liabilities of peers of DIVIS LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| DIVIS LABORATORIES | ₹196,118.2 Cr | 0.9% | 8.9% | 8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹466,179.0 Cr | -0.4% | 4.3% | 13.6% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹191,530.0 Cr | 0.7% | 13% | 46.5% | Stock Analytics | |
| CIPLA | ₹114,318.0 Cr | -1% | -0% | -3.9% | Stock Analytics | |
| MANKIND PHARMA | ₹105,068.0 Cr | -0% | 0.3% | -2.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹98,742.1 Cr | -3.3% | -8.4% | -4.3% | Stock Analytics | |
DIVIS LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| DIVIS LABORATORIES | 0.9% |
8.9% |
8% |
| SENSEX | -0.6% |
-0.1% |
-6.7% |
You may also like the below Video Courses